{"id":29362,"date":"2021-01-13T03:13:46","date_gmt":"2021-01-13T03:13:46","guid":{"rendered":"https:\/\/wames.org.uk\/cms-english\/?p=29362"},"modified":"2021-01-13T03:13:46","modified_gmt":"2021-01-13T03:13:46","slug":"ampligen-aim-doses-first-long-hauler-patient-in-trial-of-post-covid-19-infection","status":"publish","type":"post","link":"https:\/\/wames.org.uk\/cms-english\/ampligen-aim-doses-first-long-hauler-patient-in-trial-of-post-covid-19-infection\/","title":{"rendered":"Ampligen – AIM doses first \u2018long hauler\u2019 patient in trial of post-Covid-19 infection"},"content":{"rendered":"

Clinical Trial Arena: AIM doses first \u2018long hauler\u2019 patient in trial of post-Covid-19 infection,<\/a> 7 January 2021<\/h2>\n

 <\/p>\n

AIM ImmunoTech has dosed its first Covid-19 \u2018long hauler\u2019 patient in the active AMP-511 Expanded Access Program (EAP) with the Ampligen (rintatolimod) drug for the treatment of post-Covid-19 infection chronic fatigue-like symptoms.<\/strong><\/h3>\n

\"ByThe company noted that more patients are being enrolled in the trial, which is believed to be the first one to treat a patient with Covid-19-induced chronic fatigue-like symptoms.<\/p>\n

As per the Ampligen EAP protocol, at a time, it is authorised to enrol up to 100 active Chronic Fatigue Syndrome trial subjects, 20 of whom could be long haulers.<\/p>\n

All participants will be given the same Ampligen therapy in the trial.<\/p>\n

AIM CEO Thomas Equels said: \u201cThe development of an effective therapy for Covid-19-induced chronic fatigue is a critical unmet public health need.<\/p>\n

\u201cAlthough AMP-511 is not a controlled trial, patients in this AIM-sponsored study are monitored closely and it may be possible to report important observations as early as May.\u201d<\/p>\n

Last year, AIM had announced the expansion of the Ampligen-involved myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS) EAP to add in patients who were previously infected with Covid-19 and whose symptom persistence has led to the group called \u2018long haulers\u2019.<\/p>\n

According to studies, Covid-19 recovered patients can have persistence of symptoms.<\/p>\n

Furthermore, many of the first SARS-CoV-1 epidemic survivors in 2003 had classic chronic fatigue-like symptoms after they recover from acute disease.<\/p>\n

Hunter-Hopkins Center<\/a> EAP investigator Dr Charles Lapp<\/a> said:<\/p>\n

\u201cHunter-Hopkins Center is excited to have started Ampligen therapy for the first time on a Long Hauler with CFS-like symptoms.<\/p>\n

\u201cWe believe that Long Haulers experience a post-viral fatigue syndrome similar to many persons with Chronic Fatigue Syndrome, and starting treatment early and aggressively should enhance the potential to improve their symptoms and outcomes.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"

Clinical Trial Arena: AIM doses first \u2018long hauler\u2019 patient in trial of post-Covid-19 infection, 7 January 2021   AIM ImmunoTech has dosed its first Covid-19 \u2018long hauler\u2019 patient in the active AMP-511 Expanded Access Program (EAP) with the Ampligen (rintatolimod) … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[2053,5684,60,6434,6196,6435,55,2068],"class_list":["post-29362","post","type-post","status-publish","format-standard","hentry","category-news","tag-ampligen","tag-covid-19","tag-dr-charles-lapp","tag-hunter-hopkins-center","tag-long-covid","tag-long-haulers","tag-post-viral-fatigue-syndrome","tag-rintatolimod"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p5qkYK-7DA","_links":{"self":[{"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/posts\/29362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/comments?post=29362"}],"version-history":[{"count":3,"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/posts\/29362\/revisions"}],"predecessor-version":[{"id":29384,"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/posts\/29362\/revisions\/29384"}],"wp:attachment":[{"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/media?parent=29362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/categories?post=29362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/tags?post=29362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}